

## **Summary of Research Results for GOG-0286B: Testing the Addition of Metformin to Paclitaxel and Carboplatin to Treat Patients With Advanced or Recurrent Endometrial Cancer**

### **Introduction**

First and foremost, thank you for participating in this study. Your energy, effort, and willingness have the potential to help many people. Without assistance from individuals like you, making advances would be nearly impossible. This summary reviews the main results of the study. There may be benefits and risks to learning study results. A benefit for some people is knowing that they contributed to the research and their participation is appreciated. Another benefit is what was learned from the study may help them make decisions about their health care now or in the future.

For some people, a risk is getting results that make them feel distressed or remember a difficult time in their lives. Some people may feel upset about the study results if the study did not help their condition.

Please talk with your doctor about any questions you may have about this summary. Your doctor can help explain these results to you in relation to your medical concerns.

NRG Oncology thanks you for your participation in this research. Your participation has helped us learn more about your disease as described below.

### **Background of the study**

This study tested whether the drug combination of paclitaxel, carboplatin, and metformin works better than paclitaxel and carboplatin alone in treating patients with advanced or recurrent endometrial (uterine) cancer.

### **What did the study involve?**

After enrolling on this study, participants were randomized to one of two study groups. One group received paclitaxel, carboplatin, and metformin. The other group received paclitaxel, carboplatin and a placebo (a pill that looked like metformin, but contained no medication). Neither the study doctors nor the patients knew whether they were receiving metformin or the placebo.

## **What were the major findings of the study?**

A total of 469 patients were enrolled through the NRG Oncology network. An early analysis of the study deemed metformin worthy of continued investigation in the study, but a second analysis showed no difference between the metformin and placebo group and accrual to the study was stopped early. At that time, all patients who were still receiving metformin or placebo stopped receiving it.

## **Are there any steps that may need to be taken at this time or in the future for those who participated in the study?**

For participants in this study, there are no immediate or long-term steps that need to be considered because of these findings. All participants in this study have completed their treatment and should be followed by their doctor.

## **What did the researchers learn that will be helpful to other people with this condition?**

Researchers learned that treatment with metformin does not provide benefit to patients when added to carboplatin and paclitaxel compared to treatment with carboplatin and paclitaxel alone.

## **Who can I contact for further information?**

Please talk with your doctor about any questions or concerns you may have about this summary. Further details about the design, conduct and results of this study are available at [www.clinicaltrials.gov](http://www.clinicaltrials.gov). Once you access the webpage, you can search by NRG Oncology study number.

## **List of publications with references that were generated from this study.**

1. Bae-Jump VL, Sill MW, Gehrig PA, Merker JD, Corcoran DL, Pfefferle AD, Hayward MC, Walker JL, Hagemann AR, Waggoner SE, O'Cearbhaill RE, McDonald ME, Edelson MI, DiSilvestro PA, McNally AL, Fleury A, Littell RD, Ueland FR, Lankes HA, Aghajanian C. A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study. *Gynecol Oncol.* 2025 Apr;195:66-74. doi: 10.1016/j.ygyno.2025.03.003. Epub 2025 Mar 8. PMID: 40056832

